During development of resistance to vemurafenib or trametinib, NGFR signaling was either significantly suppressed (28_PLXR and 17_TRAR cells), remained unchanged (29_TRAR) or was significantly enhanced (all other resistant cell lines), whereas during immediate response the percentages of NGFR-positive cells were increased in all melanoma cell lines although to different extent (Figure 6C). This evidence concerns the gene NGFR and melanoma.